RecruitingHematologic Disease and DisordersHematopoietic Cell Transplant
Early Use of Tacrolimus in HLA-Mismatched Haploidentical Allogeneic Hematopoietic Transplantation With Post-Transplant Cyclophosphamide
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
To evalute the safety and efficacy in reducing Cytokine Release Syndrome after hematopoietic stem cell transplantation by introducing immunosuppression earlier in the transplant process
Sponsor: Northside Hospital, Inc.
You may qualify if…
- ✓ Availability of a 5/10-8/10 mismatched (HLA-A, B, DR) haploidentical related donor with a negative HLA cross-match in the host vs. graft direction and willing to provide peripheral blood stem cells
- ✓ Karnofsky status \>/= 70%
- ✓ Hematologic malignancy requiring allogeneic transplantation
- ✓ First allogeneic transplant only. Prior autologous transplant is allowed.
You may not qualify if…
- ✕ Poor cardiac function: LVEF \<40%
- ✕ Poor pulmonary function: FEV1 and FVC \<50% predicted
- ✕ Poor liver function: bilirubin \>/= 3mg/dL (not due to hemolysis, Gilbert's or primary malignancy)
- ✕ Poor renal function: Creatinine \>/= 2mg/dL or creatinine clearance (calculated or measured creatinine clearance is permitted) \<40mL/min based on Traditional Cockcroft-Gault formula
- ✕ Women of childbearing potential who currently are pregnant or who are not practicing adequate contraception
- ✕ Patients who have any debilitating medical or psychiatric illness that would preclude their giving informed consent or their receiving optimal treatment and follow up
Where it's recruiting
Georgia
Atlanta
Source: ClinicalTrials.gov · NCT06828796 · last updated 2026-04-16